FDA reconsiders on tirzepatide, big questions remain

After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list. read more →
Reporter briefing: Patient impacts of tirzepatide shortage resolution

APC's media briefing shared compounders' first-hand stories with more than 30 reporters from across the country. read more →
Be sure your marketing follows these best practices

APC's new guide will help you stay on the right side of laws and regs. read more →
A fake survey from a pharma-funded organization

What the Partnership for Safe Medicines released "Ain't a legitimate survey." read more →
Lots of letters

On the compounding front, the FDA’s inbox is getting quite a workout lately. read more →
Slick new dosing pen for compounders

Love Lifesciences’ UniPen injector pen is not only a Very Big Deal, it's available at a discount for APC PFM members. read more →
FDA says tirzepatide shortage “resolved”

As of this afternoon, the FDA Drug Shortage List is showing that the shortage of tirzepatide injection is “resolved.” Pharmacies must immediately cease preparing and dispensing compounded copies of Mounjaro and Zepbound. read more →
Get yer law and patient safety CE here

We've made the most popular segment of our 15-hour legal course into a standalone 3-hour, on-demand CE program. read more →

For the media: Semaglutide, tirzepatide, and more

Shortage Drug Compounding and GLP-1s: What you need to know

☞ On deadline? For media inquiries CLICK HERE.

Compounding snapshot: Get it now!

Upcoming Events

October 14-17: ISTX24: PCCA International Seminar, Houston

October 22: APC webinar with Pharmacists Mutual: Coverage, Claims, and Compounding: What You Need to Know About Your Liability Insurance

October 29: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (1 of 2)

November 7: APC webinar: Preservatives in Pharmacy Compounding

November 15-17: Personalized Medicine Certification Course 1: Endocrinology in St. Pete Beach, Fla.

December 4: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (2 of 2)

December 13: APC Board of Directors Meeting, Las Vegas

December 13-15: A4M Longevity Fest, Las Vegas

The Latest Resources for Compounders

Click here for more resources for compounding professionals

APC In the News

Tirzepatide fallout in The Hill:

The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.

Echoing our position:

Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As.

Wired story isn’t perfect, but…:

This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues.

Wired focuses on GLP-1 patient fallout:

Wired looks at how some patients are being hit hard by tirzepatide coming off shortage.

Quartz mentions APC:

Not a big deal, but it shows we're getting media coverage across the spectrum.

San Diego news radio focuses on GLP-1 price:

It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻

CNN gets it spot on:

The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage.

Medscape focuses on compounders:

Medscape is the latest news outlet to cover tirzepatide, and it focuses on APC's perspective.

Commenting on the tirzepatide announcement:

Since the FDA announced that tirzepatide is (for now) out of shortage, APC's Scott Brunner has been all over the news offering our perspective.

Talking about those legal threats:

Baseless but time-consuming lawsuit threats make compounders shy.

APC does its best in a Hill article:

The piece spends a lot of time considering misconceptions about compounded GLP-1s, but it least it included a little straight info from Scott.

Weighing in on Lilly’s tirzepatide vials:

Scott tells Medscape that actually helping patients with vial-based tirzepatide is a welcome change for Lilly.

Big Buttons

More News

» More APC News «